Compare WEST & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEST | RGNX |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 741.4M | 793.5M |
| IPO Year | 2022 | 2015 |
| Metric | WEST | RGNX |
|---|---|---|
| Price | $8.30 | $10.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $7.00 | ★ $28.75 |
| AVG Volume (30 Days) | 400.6K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,188,952,000.00 | $10,393,000.00 |
| Revenue This Year | $11.27 | $51.21 |
| Revenue Next Year | $10.66 | $19.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 39.76 | ★ 126.48 |
| 52 Week Low | $3.59 | $5.46 |
| 52 Week High | $10.19 | $16.19 |
| Indicator | WEST | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 48.84 |
| Support Level | $7.73 | $7.95 |
| Resistance Level | $8.50 | $11.17 |
| Average True Range (ATR) | 0.43 | 0.68 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 79.77 | 34.08 |
Westrock Coffee Co is an integrated coffee, tea, flavors, extracts, and ingredients solutions provider mainly in the United States. Additionally, it offers coffee sourcing, supply chain management, product development, roasting, packaging, and distribution services to retail, foodservice, restaurant, convenience store, travel center, non-commercial account, and hospitality industries around the world. The company's reportable segments are: Beverage Solutions and Sustainable Sourcing and Traceability. It generates maximum revenue from the Beverage Solutions segment, which offers beverage solutions, including coffee, tea, flavors, extracts, and ingredients. Geographically, the company generates maximum revenue from its business in the United States and the rest from other countries.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.